Gabrielle Campbell1, Suzanne Nielsen1, Briony Larance1, Raimondo Bruno2, Richard Mattick1, Wayne Hall3,4, Nicholas Lintzeris5,6, Milton Cohen7, Kimberley Smith1, Louisa Degenhardt1,8,9,10. 1. National Drug and Alcohol Research Centre, UNSW, Sydney, New South Wales, Australia. 2. School of Medicine, University of Tasmania, Hobart, Tasmania, Australia. 3. Centre for Youth Substance Abuse Research, University of Queensland, Herston, Queensland, Australia. 4. National Addiction Centre, Kings College, London, England. 5. Sydney Medical School, Sydney University, Herston, Queensland, Australia. 6. The Langton Centre, South East Sydney Local Health District (SESLHD) Drug and Alcohol Services, Sydney, New South Wales, Australia. 7. St Vincent's Clinical School, UNSW Medicine, UNSW, Sydney, New South Wales, Australia. 8. School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia. 9. Murdoch Children's Research Institute, Australia. 10. Department of Global Health, School of Public Health, University of Washington, Washington, USA.
Abstract
OBJECTIVE: There is increasing concern about the appropriateness of prescribing pharmaceutical opioids for chronic non-cancer pain (CNCP), given the risks of problematic use and dependence. This article examines pharmaceutical opioid dose and dependence and examines the correlates of each. DESIGN: Baseline data were obtained from a national sample of 1,424 people across Australia (median 58 years, 55% female and experiencing pain for a median of 10 years), who had been prescribed opioids for CNCP. Current opioid consumption was estimated in oral morphine equivalent (OME; mg per day), and ICD-10 pharmaceutical opioid dependence was assessed using the Composite International Diagnostic Interview. RESULTS: Current opioid consumption varied widely: 8.8% were taking <20 mg OME per day, 52.1% were taking 21-90 mg OME, 24.3% were taking 91-199 mg OME, and 14.8% were taking >= 200 mg OME. Greater daily OME consumption was associated with higher odds of multiple physical and mental health issues, aberrant opioid use, problems associated with opioid medication and opioid dependence. A significant minority, 8.5%, met criteria for lifetime ICD-10 pharmaceutical opioid dependence and 4.7% met criteria for past year ICD-10 pharmaceutical opioid dependence. Multivariate analysis found past-year dependence was independently associated with being younger, exhibiting more aberrant behaviors and having a history of benzodiazepine dependence. CONCLUSIONS: In this population of people taking opioids for CNCP, consumption of higher doses was associated with increased risk of problematic behaviors, and was more likely among people with a complex profile of physical and mental health problems. Wiley Periodicals, Inc.
OBJECTIVE: There is increasing concern about the appropriateness of prescribing pharmaceutical opioids for chronic non-cancer pain (CNCP), given the risks of problematic use and dependence. This article examines pharmaceutical opioid dose and dependence and examines the correlates of each. DESIGN: Baseline data were obtained from a national sample of 1,424 people across Australia (median 58 years, 55% female and experiencing pain for a median of 10 years), who had been prescribed opioids for CNCP. Current opioid consumption was estimated in oral morphine equivalent (OME; mg per day), and ICD-10 pharmaceutical opioid dependence was assessed using the Composite International Diagnostic Interview. RESULTS: Current opioid consumption varied widely: 8.8% were taking <20 mg OME per day, 52.1% were taking 21-90 mg OME, 24.3% were taking 91-199 mg OME, and 14.8% were taking >= 200 mg OME. Greater daily OME consumption was associated with higher odds of multiple physical and mental health issues, aberrant opioid use, problems associated with opioid medication and opioid dependence. A significant minority, 8.5%, met criteria for lifetime ICD-10 pharmaceutical opioid dependence and 4.7% met criteria for past year ICD-10 pharmaceutical opioid dependence. Multivariate analysis found past-year dependence was independently associated with being younger, exhibiting more aberrant behaviors and having a history of benzodiazepine dependence. CONCLUSIONS: In this population of people taking opioids for CNCP, consumption of higher doses was associated with increased risk of problematic behaviors, and was more likely among people with a complex profile of physical and mental health problems. Wiley Periodicals, Inc.
Authors: John Strang; Nora D Volkow; Louisa Degenhardt; Matthew Hickman; Kimberly Johnson; George F Koob; Brandon D L Marshall; Mark Tyndall; Sharon L Walsh Journal: Nat Rev Dis Primers Date: 2020-01-09 Impact factor: 52.329
Authors: Jin Han; Jifang Zhou; Santosh L Saraf; Victor R Gordeuk; Gregory S Calip Journal: Pharmacoepidemiol Drug Saf Date: 2017-08-16 Impact factor: 2.890
Authors: Francisca N Wagemaakers; Samantha A Hollingworth; Sanne Kreijkamp-Kaspers; Ernest H L Tee; Anne J Leendertse; Mieke L van Driel Journal: Int J Clin Pharm Date: 2017-06-12
Authors: Aymen Ali Al-Qurain; Lemlem G Gebremichael; Mohammed S Khan; Desmond B Williams; Lorraine Mackenzie; Craig Phillips; Patrick Russell; Michael S Roberts; Michael D Wiese Journal: Int J Clin Pharm Date: 2020-11-18
Authors: Jin Han; Santosh L Saraf; Xu Zhang; Michel Gowhari; Robert E Molokie; Joharah Hassan; Chaher Alhandalous; Shivi Jain; Jewel Younge; Taimur Abbasi; Roberto F Machado; Victor R Gordeuk Journal: Am J Hematol Date: 2016-08-08 Impact factor: 10.047